She is particularly interested in the identification of cancer driver mutations, genes and
pathways across tumor types and in the study of their targeted opportunities.
Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs,
across tumor types.
The partnership will seek approval for a version of the Illumina's test, TruSight Tumor 170, as a companion diagnostic for Loxo's larotrectinib and another one of Loxo's experimental cancer drugs,
across tumor types.